Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.32 |
| ▸ | AOC1 | P19801 | 3/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 2/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773980 | 0.97 | GABRA1 (0.33) | AOC1AOC3GABRA1GABRB2BACE1 | |
| Bromide SCHEMBL6625824 | 0.95 | GABRA1 (0.32) | GABRA1GABRB2BACE1PSIP1CTRC | |
| SCHEMBL11328090 | 0.93 | GABRA1 (0.31) | GABRA1GABRB2BACE1PSIP1CTRC | |
| SCHEMBL166573 | 0.84 | GABRA1 (0.41) | GABRA1GABRB2CTRCTAAR1NOS3 | |
| SCHEMBL29619533 | 0.84 | GABRA1 (0.41) | GABRA1GABRB2CTRCTAAR1NOS3 | |
| SCHEMBL3967214 | 0.83 | GABRA1 (0.46) | GABRA1GABRB2PSIP1PNMTTAAR1 | |
| SCHEMBL12797846 | 0.81 | GABRA1 (0.36) | AOC3GABRA1GABRB2BACE1PSIP1 | |
| Water SCHEMBL5507579 | 0.81 | GABRA1 (0.44) | GABRA1GABRB2PSIP1PNMTTAAR1 | |
| SCHEMBL9278587 | 0.81 | POLB (0.32) | AOC1AOC3GABRA1GABRB2NOS3 | |
| Ammonia Solution, Strong SCHEMBL27539208 | 0.81 | GABRA1 (0.39) | GABRA1GABRB2CTRCTAAR1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3078659-B1 | 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | JENKEM TECH CO LTD (BEIJING) (CN) | 2017-11-15 | — | — | EP | claimed |
| EP-3078659-A1 | 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Jenkem Technology Co. Ltd. (Beijing) (CN) | 2016-10-12 | — | — | EP | claimed |
| US-20160272604-A1 | 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2016-09-22 | — | — | US | claimed |
| US-9834530-B2 | 3-furyl-2-cyano-2-acrylamide derivative, preparation method therefor, pharmaceutical composition and use thereof | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2017-12-05 | — | — | US | disclosed |
| EP-3078659-B1 | 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | JENKEM TECH CO LTD (BEIJING) (CN) | 2017-11-15 | — | — | EP | disclosed |
| EP-3078659-A1 | 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Jenkem Technology Co. Ltd. (Beijing) (CN) | 2016-10-12 | — | — | EP | disclosed |
| US-20160272604-A1 | 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | JENKEM TECHNOLOGY CO., LTD. (BEIJING) (CN) | 2016-09-22 | — | — | US | disclosed |
| EP-2330891-A1 | FUNGICIDAL PYRIDAZINES | E. I. du Pont de Nemours and Company (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010036553-A1 | FUNGICIDAL PYRIDAZINES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| CN-100525766-C | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-12 | — | — | CN | disclosed |
| EP-1874304-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-09 | — | — | EP | disclosed |
| EP-1000040-B1 | IL-5 INHIBITING 6-AZAURACIL DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006117307-A2 | BENZOTRIAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
| CN-1762355-A | (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation | JANSSEN PHARMACEUTICA NV (BE) | 2006-04-26 | — | — | CN | disclosed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
| CN-1231215-C | (imidazol-5-yl) methyl-2-quinolinone derivatives as smooth muscle cell proliferation inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-14 | — | — | CN | disclosed |
| CN-1265585-A | (imidazol-5-yl) methyl-2-quinolinone derivatives as smooth muscle cell proliferation inhibitors | JANSSEN PHARMACEUTICA NV (NL) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | GABRA1 1672/4885GABRB2 1658/4885AOC1 1010/4885 |
| US-20160272604-A1 | 3-FURYL-2-CYANO-2-ACRYLAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | EGFR, ERBB2, ERBB3 | GABRA1 587/4885GABRB2 817/4885AOC1 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.